ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

Watch the video

News

See all

Post date
07/30/2021

ALK and Grandpharma team up to market the first adrenaline autoinjector in China

Read more
Post date
07/10/2021

New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress

Read more
Post date
05/10/2021

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
05/05/2021

Three-month interim report (Q1) 2021

Read more
Post date
04/28/2021

Release date of three-month interim report (Q1) 2021 for ALK and audio cast

Read more
Post date
04/19/2021

ALK gains paediatric approval for its ragweed SLIT-tablet in the USA

Read more
Post date
03/26/2021

Grant of share options and performance shares to members of the Board of Management and key employees

Read more
Post date
03/18/2021

Annual General Meeting in ALK-Abelló A/S held on 18 March 2021

Read more
Post date
03/10/2021

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more

ALK supports eSOSA 2021

The SOSA programme includes the most recent updates in the field of specific allergy. The scientific programme for SOSA is developed by a pre-eminent International Scientific Committee and involves a faculty of around 35 distinguished speakers from the allergy scientific community. In 2021, to adapt to the COVID-19 limitations, SOSA will be held as a virtual event: eSOSA 2021.

Strategy update: Focus areas during 2021-23

Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

Seasonal allergy symptoms can be confused with COVID-19

Therefore allergy symptoms should be kept under the best possible control. Watch Dr Glenis Scadding's expert advise in respect of seasonal allergies and COVID-19.

For further information visit EUFOREA

seasonal_allergic_rhinitis_in_relation_to_covid-19

ALK in brief

Allergy at a glance

Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.

Our solutions

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.